Cardiovascular disease: Pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke

American Journal of Obstetrics and Gynecology

Volumn 180, Issue 7 II, 1999, Pages

  Castelli, W P ^a  

^a Framingham Cardiovascular Institute   (United States)

Author keywords

Cardiovascular disease; Lung cancer; Oral contraceptives; Smoking

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DEEP VEIN THROMBOSIS; DOSE RESPONSE; FEMALE; GENE MUTATION; HUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032976312     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9378(99)70695-2     Document Type: Review

References (46)

1. National Center for Health Statistics Vital statistics of the United States, 1988, vol 2: mortality, part A 1991 US Department of Health and Human Services, Public Health Service, Centers for Disease Control Hyattsville (MD)
2. RA Wild EL Taylor A. Knehans The gynecologist and the prevention of cardiovascular disease Am J Obstet Gynecol 172 1995 1 13
3. WP Castelli Cardiovascular disease in women Am J Obstet Gynecol 158 1988 1553 1560
4. WB Kannel M. Higgins Smoking and hypertension as predictors of cardiovascular risk in population studies J Hypertens 8 1990 S3 S8
5. RO Bonow V. Dilsizian Thallium 201 for assessment of myocardial viability Semin Nucl Med 21 1991 230 241
6. E Falk PK Shah V. Fuster Coronary plaque disruption Circulation 92 1995 657 671
7. RA Vogel MC Corretti GD Plotnick Effect of a single high-fat meal on endothelial function in healthy subjects Am J Cardiol 79 1997 350 354
8. CB Treasure JL Klein WS Weintraub JD Talley ME Stillabower AS Kosinski Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease N Engl J Med 332 1995 481 487
9. TJ Anderson IT Meredith AC Yeung B Frei AP Selwyn P. Ganz The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion N Engl J Med 332 1995 488 493
10. JR Downs M Clearfield S Weis E Whitney DR Shapiro PA Beere the AFCAPS/TexCaps Research Group Primary preventions of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCaps JAMA 279 1998 1615 1622
11. M Poapst M Reardon G. Steiner Relative contribution of triglyceride-rich lipoprotein particle size and number to plasma triglyceride concentration Arteriosclerosis 5 1985 381 390
12. MA Austin MC King KM Vranizan RP Krauss Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk Circulation 82 1990 495 506
13. I Juhan-Vague D. Collen On the role of coagulation and fibrinolysis in atherosclerosis Ann Epidemiol 2 1992 427 438
14. JP Vandenbroucke T Koster E Brilet PH Reitsma RM Bertina FR Rosendaal Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation Lancet 344 1994 1453 1457
15. KW Bloemenkamp FR Rosendaal FM Helmerhorst HR Büller JP Vandenbroucke Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen Lancet 346 1995 1593 1596
16. VL Burt P Whelton EJ Roccella C Brown JA Cutler M Higgins Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991 Hypertension 25 1995 305 313
17. Anonymous The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) Arch Intern Med 153 1993 154 183
18. American College of Obstetricians and Gynecologists Hormonal contraception 1994 The College Washington, DC 1 13 ACOG Technical Bulletin
19. TW Meade AP Haines WR North R Chakrabarti DJ Howarth Y. Stirling Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen Lancet 2 1977 948 951
20. Ø. Lidegaard Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study BMJ 306 1993 956 963
21. A Basdevant J Conard C Pelissier TT Guyene C Lapousterle M Mayer Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel Contraception 48 1993 193 203
22. E. Ernst Plasma fibrinogen: an independent cardiovascular risk factor J Intern Med 227 1990 365 372
23. J Heinrich L Balleisen H Schulte G Assmann J. van de Loo Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men [published erratum appears in Arterioscler Thromb 1994;14:1392] Arterioscler Thromb 14 1994 54 59
24. JW Yarnell IA Baker PM Sweetnam D Bainton JR O’Brien PJ Whitehead Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies Circulation 83 1991 836 844
25. GJ Miller Environmental influences on hemostasis and thrombosis: diet and smoking Ann Epidemiol 2 1992 387 391
26. CC Kelleher Plasma fibrinogen and factor VII as risk factors for cardiovascular disease Eur J Epidemiol 8 suppl 1 1992 79 82
27. TW Meade V Ruddock Y Stirling R Chakrabarti GJ Miller Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study Lancet 342 1993 1076 1079
28. MR Adams TB Clarkson CA Shively JS Parks JR Kaplan Oral contraceptives, lipoproteins, and atherosclerosis Am J Obstet Gynecol 163 1990 1388 1393
29. WN Spellacy WC Buhi SA Birk The effects of norgestrel on carbohydrate and lipid metabolism over one year Am J Obstet Gynecol 125 1976 984 986
30. IF Godsland D Crook R Simpson T Proudler C Felton B Lees The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism N Engl J Med 323 1990 1375 1381
31. UJ Gaspard PJ Lefebvre Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease Am J Obstet Gynecol 163 1990 334 343
32. P Wahl C Walden R Knopp J Hoover R Wallace G Heiss Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol N Engl J Med 308 1983 862 867
33. Anonymous Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 346 1995 1582 1588
34. H Jick SS Jick V Gurewich MW Myers C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593
35. J Rosing G Tans GA Nicolaes MC Thomassen R van Oerle PM van der Ploeg Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives Br J Haematol 97 1997 233 238
36. MA Lewis LA Heinemann KD MacRae R Bruppacher WO Spitzer The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women Contraception 54 1996 5 13
37. KW Bloemenkamp FR Rosendaal HR Büller FM Helmerhorst LP Colly JP Vandenbroucke Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias Arch Intern Med 159 1998 65 70
38. MJ Stampfer WC Willet GA Colditz FE Speizer CH Hennekens A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases N Engl J Med 319 1988 1313 1317
39. Anonymous Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners’ Oral Contraception Study Lancet 1 1981 541 546
40. P Croft P. Hannaford Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study BMJ 21 1989 165 168
41. Anonymous Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 349 1997 1202 1209
42. DH Barrett RF Anda LG Escobedo JB Croft DF Williamson JS Marks Trends in oral contraceptive use and cigarette smoking; behavioral risk factors surveillance system, 1982 and 1988 Arch Fam Med 3 1994 438 443
43. GN Mileikowsky JL Nadler F Huey R Francis S. Roy Evidence that smoking alters prostacyclin formation and platelet aggregation in women who use oral contraceptives Obstet Gynecol 159 1988 1547 1552
44. C Rångemark G Benthin EF Granström L Persson S Winell A. Wennmalm Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age Circulation 86 1992 1495 1500
45. F Fruzzetti C Ricci P. Fioretti Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives Contraception 49 1994 579 589
46. E Kawachi GA Colditz M Stampfer WC Willett JA Manson B Rosner Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women Arch Intern Med 154 1994 169 175